Furthermore, the detection results were positively correlated with the clinical stages, and the comparison study demonstrated that LC3+ EVs were more reliable in distinguishing peripheral blood from cancer patients with different clinical stages than traditional biomarkers, such as CEA and CA15-3. Here, MAP1LC3A is linked to cancer.